Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, including a triple-combo LDL-C pill and liver/kidney therapies, could be transformative, but near-term catalysts hinge on execution and proof of profitability.
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year.
Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Conference Call Participants Dennis Ding - Jefferies Joseph Pantginis - H.C. Wainwright Jason Zemansky - Bank of America Kristen Kluska - Cantor Fitzgerald Jessica Fye - J.P.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.34 per share a year ago.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Esperion Therapeutics (ESPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases
Esperion Appoints Robert E. Hoffman to Board of Directors
- Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E.
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
